A5320: Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)

Study Location:

BaltimoreWashington

Topic:

Hepatitis and HIV

Clinicaltrials.gov Link:

N/A

IRB#:

NA_00092078

Coordinator:

Ilene Wiggins, RN (Baltimore)

Anna Wimpelberg (Washington)

Enrollment:

Open

Trial Period:

Ongoing

A5320/V-HICS is an observational, prospective, long-term follow-up study in hepatitis C virus (HCV) monoinfected and HCV/HIV-1 coinfected participants who received direct-acting antiviral (DAA) therapy for HCV infection.

Men and women ≥ 18 years old, HCV/HIV-1 coinfected who failed HCV therapy any time after HCV/DAA treatment discontinuation (non-SVR); or HCV monoinfected who failed HCV therapy any time after HCV/DAA treatment discontinuation (non-SVR); or HCV/HIV-1 coinfected participants who achieved a SVR at least 12 weeks after treatment completion; or HCV monoinfected participants who achieved a SVR as at least 12 weeks after treatment completion.

Anna Wimpelberg (Washington)
202-797-3589
awimpelberg@whitman-walker.org


​Ilene Wiggins, RN (Baltimore)
410-614-2766
iwiggin1@jhmi.edu

Categories

Location
Topic

Clinical Trials

A5282: A Randomized, Phase II Trial to Compare an HPV...

The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to...

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More